<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643276</url>
  </required_header>
  <id_info>
    <org_study_id>AIEOP-BFM ALL 2017</org_study_id>
    <nct_id>NCT03643276</nct_id>
  </id_info>
  <brief_title>Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017</brief_title>
  <official_title>International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Schrappe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has
      largely changed due to extensive genetic research in recent years: ALL is now considered to
      be a very heterogeneous disease group. The leukemia cells present themselves with quite
      differently activated regulatory mechanisms of the malignant phenotype. The introduction of
      more accurate methods of assessing therapy response (&quot;minimal residual disease [MRD] tests&quot;)
      has provided new insights into very different mechanisms of action, including factors
      influenced by host factors; this has had practical clinical consequences for the use of more
      individualized therapy. Multimodal therapies have enabled a cure level of over 80% for ALL in
      this age group. However, the own and international study data show that the therapy toxicity
      of the contemporary chemotherapy concepts has become unacceptably high, in particular with
      respect to those intensified therapies used for the treatment of patients at high risk of ALL
      relapse.

      The AIEOP-BFM ALL 2017 study therefore aims for an innovative integrated approach that will
      not only adapt the risk stratification to new prognostic markers using more comprehensive
      diagnostics, but above all, qualitatively reorient the therapy. The most important
      consequence will be that this study is testing immunotherapy with the bispecific antibody
      blinatumomab as an alternative to particularly intensive and toxic chemotherapy elements in
      precursor B-cell ALL (pB-ALL) patients with detectable chemotherapy resistance and at high
      risk of relapse. With the aim to complement the effects of the conventional chemotherapy,
      Blinatumomab is in addition tested in the large group of pB-ALL patients at intermediate
      relapse risk with seemingly unremarkable leukemia, but who account for a large proportion of
      all relapses. Targeted therapy is also used in the form of the proteasome inhibitor
      bortezomib for patients with pB-ALL and slow response to the drugs of the induction
      chemotherapy with the aim to overcome intrinsic chemotherapy resistance of the ALL cells. In
      patients with T-lineage ALL, who have particularly poor chances for cure after relapse, the
      established consolidation chemotherapy has proved to be particularly effective. This
      chemotherapy phase is therefore tested in a longer and more intensive form in such T-ALL
      patients with intermediate or slow early treatment response with the aim to reduce the
      relapses rate in this subgroup.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are stratified into 4 early risk groups for therapy during the consolidation phase
      (T/early SR, T/early non-SR, pB/early non-HR, pB/early HR) and 5 risk groups for
      post-consolidation therapy (T/non-HR, T/HR, pB/SR, pB/MR, pB/HR). Risk stratification is
      based on immunophenotypic lineage, genetics of leukemic cells and treatment response on the
      basis of cytomorphology and methods for detection minimal residual disease.

      The trial includes four randomized study questions testing experimental treatments on top of
      the risk-stratified standard chemotherapy backbone:

      Primary study questions:

      Randomization R-eHR: Early High-risk (early HR) pB-ALL defined by genetics and/or inadequate
      treatment response over the course of induction: Can the probability of event-free survival
      (pEFS) from time of randomization be improved by additional therapy with the proteasome
      inhibitor bortezomib during an extended consolidation treatment phase compared with standard
      extended consolidation?

      Randomization R-HR: High-risk (HR) pB-ALL defined by genetics and/or inadequate treatment
      response by the end of consolidation: Can the pEFS from time of randomization be improved by
      a treatment concept including two cycles of post-consolidation immunotherapy with
      blinatumomab (15 µg/m²/d for 28 days per cycle) plus 4 doses intrathecal Methotrexate
      replacing two conventional highly intensive chemotherapy courses?

      Randomization R-MR: Intermediate risk (MR) pB-ALL defined by genetics and intermediate MRD
      response: Can the probability of disease-free survival (pDFS) from time of randomization be
      improved by additional therapy with one cycle of post-reintensification immunotherapy with
      blinatumomab (15 µg/m²/d for 28 days)?

      Randomization R-T: Early non-standard risk (early non-SR) T-ALL patients defined by treatment
      response over the course of induction: Can the pEFS from time of randomization be improved by
      the extension of the standard of care consolidation phase by 14 days with an increase of the
      consolidation cumulative doses of Cyclophosphamide, Cytarabine and 6-Mercaptopurine by 50%?

      Secondary study questions:

      All randomizations: Can the overall survival be improved by the treatment in the experimental
      arm?

      All randomizations: What is the incidence of treatment-related toxicities and mortality in
      the experimental arm compared to the standard arm?

      Randomization R-eHR: Can the MRD load after consolidation treatment be reduced by the
      additional treatment with bortezomib?

      Randomization R-HR: Can treatment-related life-threatening complications and mortality during
      the intensified consolidation phase of high-risk treatment be reduced when replacing two
      intensive chemotherapy courses by two cycles of immunotherapy with blinatumomab?

      Randomization R-HR: What is the proportion of patients with insufficient MRD response to
      blinatumomab as defined in the protocol as compared to the MRD response after the HR-2' block
      in the control arm?

      Randomization R-HR: Can the MRD load after the first treatment cycle (HR 2'/blinatumomab) and
      the second cycle (HR-3'/blinatumomab) be reduced in the experimental arm when compared with
      conventional intensive chemotherapy? Randomization R-MR: What is the proportion of patients
      with positive MRD after reintensification Protocol II who become MRD-negative over the
      blinatumomab cycle compared to 4 weeks of standard maintenance therapy?

      Randomization R-T: Can the MRD load after consolidation treatment be reduced by extension of
      the consolidation phase?

      Standard-risk patients: Is the clinical outcome comparable to that obtained for standard-risk
      patients in study AIEOP-BFM ALL 2009?

      A small subgroup of patients at very high relapse risk is eligible for allogeneic
      hematopoietic stem cell transplantation after the intensified consolidation therapy phase.

      Patients with T-ALL and hyperleukocytosis (&gt;=100,000/µL) and patients with CNS involvement at
      diagnosis (CNS3 status) are eligible for cranial irradiation with 12 Gy if age at time of
      irradiation is at least 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">July 14, 2028</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>pB-ALL/MR: 2 parallel groups (R-MR) or 2x2 factorial design (R-eHR, R-MR) depending on early risk group assignment.
pB-ALL/HR: 2 parallel groups (R-HR) or 2x2 factorial design (R-eHR, R-HR) depending on early risk group assignment.
T-ALL/early non-SR: 2 parallel groups (R-T).
pB-ALL/SR: Single group.
T-ALL/early SR: Single group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>Randomization R-eHR, R-HR and R-T: Time from randomization until the first event defined as follow: cytomorphological or molecular non-response (resistance to protocol treatment, considered as event at day zero), relapse, second malignancy or death from any cause. This will be called EFS time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>Randomization R-MR: Time from randomization until the first event defined as follow: Relapse, second malignancy or death from any cause. This will be called DFS time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>All patients/randomizations: Time until death from any cause, starting at the same time point as the EFS/DFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>Frequency and incidence of treatment-related mortality in induction or continuous complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events of interest/Serious Adverse Events</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>Frequency and incidence of adverse events of interest and serious adverse events in specific protocol phases, randomized arms and overall during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD response</measure>
    <time_frame>Measurements of MRD response at end of randomized treatments (intended time frame 13 weeks in R-eHR/R-T, 26 weeks in R-HR, 34 weeks in R-MR).</time_frame>
    <description>MRD load after the randomized treatment phases (R-eHR, R-HR, R-MR and R-T) as well as after the first/second cycle of Blinatumomab or after the HR 2'/HR 3' block (R-HR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Blina Poor-Response</measure>
    <time_frame>Measurements of MRD response intended after 30 weeks from individual start of treatment, assessment of proportion at 120 months from start of study</time_frame>
    <description>Proportion of patients with poor MRD response to the first Blinatumomab cycle (&quot;Blinatumomab Poor-Response&quot;) (R-HR)</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Acute Lymphoblastic Leukemia, Pediatric</condition>
  <arm_group>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction (5 wks): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)
Consolidation (6 w/4 w): &quot;Consolidation extended&quot; (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or &quot;Consolidation short&quot; (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
Extra-compartment phase (8 wks): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX
Reinduction (6 wks): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
Maintenance (until 2 years after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
Consolidation (6 w): &quot;Consolidation extended+BZM&quot; (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)
Extra-compartment phase (8 wks): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX
Reinduction (6 wks): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
Consolidation (6 w/4 w): &quot;Consolidation extended&quot; (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or &quot;Consolidation short&quot; (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
Extra-compartment phase (8 w): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX
Reinduction (6 w): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
Consolidation (6 w): &quot;Consolidation extended+BZM&quot; (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)
Extra-compartment phase (8 w): &quot;Protocol M&quot; with 6-MP, HD-MTX,IT MTX
Reinduction (6 weeks): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine
Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)
Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction (5 w): as in other pB arms
Consolidation (6 w/4 w): &quot;Consolidation extended&quot; (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or &quot;Consolidation short&quot; (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX
Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide
Reinduction (3x4 w): &quot;Protocol III&quot; given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX
Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): as in other pB arms
Consolidation (6 w): &quot;Consolidation extended+BZM&quot; (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)
Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide
Reinduction (3x4 w): as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): as in other pB arms
Consolidation (6 w/4 w): &quot;Consolidation extended&quot; (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or &quot;Consolidation short&quot; (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX
Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)
Reinduction (3x4 weeks): as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot;
Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX
Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): as in other pB arms
Consolidation (6 w): &quot;Consolidation extended+BZM&quot; (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)
Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)
Reinduction (3x4 weeks): as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot; Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX
Consolidation (4 w): &quot;Consolidation short&quot; with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
Extra-compartment phase (8 w): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX
Reinduction (6 w): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA-Dexa&quot; with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or &quot;Protocol IA-CPM&quot; with prednisolone instead of dexamethasone and additional CPM
Consolidation (4 w): &quot;Protocol IB regular&quot; (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
non-HR extra-compartment phase and reinduction: as in arm &quot;pB: early non-HR/SR&quot;
HR intensified consolidation and reinduction: as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA-Dexa&quot; with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or &quot;Protocol IA-CPM&quot; with prednisolone instead of dexamethasone and additional CPM
Consolidation (6 w): &quot;Protocol IB long&quot; (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
non-HR extra-compartment phase and reinduction: as in arm &quot;pB: early non-HR/SR&quot;
HR intensified consolidation and reinduction: as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive DNX-FLA (liposomal daunorubicin, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA-Dexa&quot; with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX
Consolidation (4 w): &quot;Protocol IB regular&quot; with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX
Extra-compartment phase (8 w): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX
Reinduction (6 w): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Experimental therapy in randomizations R-HR and R-MR</description>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Experimental therapy in randomization R-eHR</description>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block DNX-FLA for patients with very high relapse risk</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAUNOrubicin Liposomal Injection [DaunoXome]</intervention_name>
    <description>Part of intensification block DNX-FLA for patients with very high relapse risk</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <other_name>Liposomal Daunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Part of intensification block DNX-FLA for patients with very high relapse risk</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Mercaptopurine</intervention_name>
    <description>Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tioguanin</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vindesine</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erwinase</intervention_name>
    <description>Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed acute lymphoblastic leukemia or

          -  newly diagnosed mixed phenotype acute leukemia (MPAL) meeting one of the following
             criteria:

          -  biphenotypic with a dominant T or B lineage assignment

          -  bilineal either with a dominant lymphoblastic population or if another reasonable
             rationale exists to treat the patient with an ALL-based therapy regimen

          -  newly diagnosed acute undifferentiated leukemia

          -  age &lt; 18 years (up to 17 years and 365 days) at the day of diagnosis

          -  patient enrolled in a participating center

          -  written informed consent to trial participation and transfer and processing of data A
             subsequent removal from the study is only allowed if the inclusion criteria turn out
             not to be fulfilled or in the case of pregnancy of the patient.

        Exclusion Criteria:

          -  Ph+ (BCR-ABL1 or t(9;22)-positive) ALL

          -  bilineal leukemia with a lymphoblastic and a separate non-lymphoblastic (≥ 10% of
             total cells) blast subset

          -  pre-treatment with cytostatic drugs

          -  glucocorticoid pre-treatment with ≥ 1 mg/kg/d for more than two weeks during the last
             month before diagnosis

          -  treatment started according to another protocol

          -  underlying disease that does not allow treatment according to the protocol (e.g.
             severe congenital heart disease, Charcot-Marie Syndrome, Ataxia-teleangiectasia…)

          -  ALL diagnosed as second malignancy and preceding chemotherapy and/or radiotherapy

          -  evidence of pregnancy or lactation period

          -  Sexually active adolescents not willing to use highly effective contraceptive method
             (pearl index &lt;1) until 12 months after end of anti-leukemic therapy

          -  participation in another clinical trial except for add-on trials within the scope of
             supportive care approved by the sponsor

          -  live vaccine immunization within 2 weeks before start of protocol treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schrappe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Kiel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Möricke, MD</last_name>
    <phone>+4943150020150</phone>
    <email>a.moericke@pediatrics.uni-kiel.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lile Bauer</last_name>
    <phone>+4943150020152</phone>
    <email>lile.bauer@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Heath</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perth Children's Hospital</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rishi Kotecha</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Hunter Children's Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Alvaro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Draga Barbaric</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luciano Dalla-Pozza</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ.Klinik für Kinder- und Jugendheilkunde Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Benesch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernhard Meister</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Ebetsberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Jones</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andishe Attarbaschi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslav Štěrba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiří Hak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Pospíšilová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava-Poruba</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomáš Kuhn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Plzeň</name>
      <address>
        <city>Plzeň</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomáš Votava</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Starý</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masaryk´s Hospital Ústí nad Labem</name>
      <address>
        <city>Ústí nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Procházková</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Hospital České Budějovice</name>
      <address>
        <city>České Budějovice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Timr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik der med. Fakultät der RWTH, Bereich Hämatologie/Onkologie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udo Kontny</last_name>
      <phone>+49 241808</phone>
      <phone_ext>9902</phone_ext>
      <email>ukontny@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>I. Klinik für Kinder u. Jugendliche, Klinikum Augsburg, Hämatologie/ Onkologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Frühwald</last_name>
      <phone>+49 821400</phone>
      <phone_ext>3631</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lothar Schweigerer</last_name>
      <phone>+49 309401</phone>
      <phone_ext>2367</phone_ext>
      <email>lschweigerer@berlin.helio-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik der Charité, Campus Virchow Klinikum (CVK), Abt.: Kinderhämatologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arend Stackelberg</last_name>
      <phone>+49 30450566</phone>
      <phone_ext>833</phone_ext>
      <email>arend.stackelberg@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus, Kinderklinik</name>
      <address>
        <city>Braunschweig</city>
        <zip>38118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Eberl</last_name>
      <phone>+49 531595</phone>
      <phone_ext>1424</phone_ext>
      <email>w.eberl@klinkum-braunschweig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie / Onkologie</name>
      <address>
        <city>Chemnitz</city>
        <zip>09009</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Hofmann</last_name>
      <phone>+49 3713332</phone>
      <phone_ext>4287</phone_ext>
      <email>a.hofmann@skc.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum, Kinderklinik, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Schwabe</last_name>
      <phone>+49 35546</phone>
      <phone_ext>2332</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vestische Kinder- u. Jugendklinik, Universitätsklinik Witten/Herdecke</name>
      <address>
        <city>Datteln</city>
        <zip>45711</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wiesel</last_name>
      <phone>+49 236397</phone>
      <phone_ext>5846</phone_ext>
      <email>th.wiesel@kinderklinik-datteln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund, Klinik f. Kinder- und Jugendmedizin</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Schneider</last_name>
      <phone>+49 2319532</phone>
      <phone_ext>1050</phone_ext>
      <email>dominik.schneider@klinikumdo.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Knöfler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Borkhardt, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH, Klinik für Kinderheilkunde</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Sauerbrey</last_name>
      <phone>+49 36178</phone>
      <phone_ext>4501</phone_ext>
      <email>axel.sauerbrey@helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Metzler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Beier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Klingebiel, MD</last_name>
      <phone>49-69-6301-5094</phone>
      <email>thomas.klingebiel@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetskinderklinik - Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Niemeyer, MD</last_name>
      <phone>49-761-270-4506</phone>
      <email>charlotte.niemeyer@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Justus-Liebig-Universität, Zentrum für Kinderheilkunde, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Gießen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Mauz-Körholz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Kinder und Jugendmedizin, Allgemeine Pädiatrie mit Poliklinik/Pädiatrische Onkologie und Hämatologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Lode</last_name>
      <phone>+49 383486</phone>
      <phone_ext>6325</phone_ext>
      <email>holger.lode@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik Päd. I, Hämatologie/Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Kühnle</last_name>
      <phone>+49 55139</phone>
      <phone_ext>6201</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Zentrum Kinderheilkunde u. Jugendmedizin</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christin Linderkamp</last_name>
      <phone>+49 511532</phone>
      <phone_ext>6710</phone_ext>
      <email>linderkamp.christin@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik, Päd. Onkologie, Hämatologie, und Immunologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Behnisch</last_name>
      <phone>+49 622156</phone>
      <phone_ext>4555</phone_ext>
      <email>wolfgang.behnisch@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Heilbronn GmbH, Klinik für Kinderheilkunde und Jugendmedizin/Perinatalzentrum</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Full</last_name>
      <phone>+49 713149</phone>
      <phone_ext>3702</phone_ext>
      <email>hermann.full@slk-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus Herdecke, Kinderabteilung</name>
      <address>
        <city>Herdecke</city>
        <zip>58313</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Längler</last_name>
      <phone>+49 233062</phone>
      <phone_ext>3893</phone_ext>
      <email>a.laengler@gemeinschaftskrankenhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Graf</last_name>
      <phone>49-6841-168-8397</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum, der Friedrich-Schiller-Universität, Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Jena</city>
        <zip>7740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Gruhn</last_name>
      <phone>+49 364193</phone>
      <phone_ext>8220</phone_ext>
      <email>bernd.gruhn@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Leipold</last_name>
      <phone>49-721-9740</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>D-34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Nathrath, MD</last_name>
      <phone>49-561-980-3382</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Allgemeine Paediatrie, Univ.-Klinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schrappe</last_name>
      <phone>+49 431597</phone>
      <phone_ext>1620</phone_ext>
      <email>m.schrappe@pediatrics.uni-kiel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln GmbH, Kinderkrankenhaus Riehl</name>
      <address>
        <city>Köln</city>
        <zip>50735</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aram Prokop</last_name>
      <phone>+49 2218907</phone>
      <phone_ext>5158</phone_ext>
      <email>prokopa@klinken-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Einrichtungen der Universität zu Köln, Klinik für Allg. Kinderheilkunde, Onkologisch-hämatologische Station</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Simon</last_name>
      <phone>+49 221478</phone>
      <phone_ext>4380</phone_ext>
      <email>thorsten.simon@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department für Frauen- und Kindermedizin, Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Fischer</last_name>
      <phone>0341-97 26</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universität zu Lübeck, Klinik für Kinder- u. Jugendmedizin, Abt. Hämatologie/ Onkologie/Immunologie</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melchior Lauten</last_name>
      <phone>+49 451500</phone>
      <phone_ext>2557</phone_ext>
      <email>lauten@paedia.ukl.mu-luebeck.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg, Klinik für Päd. Hämatologie/Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Vorwerk</last_name>
      <phone>+49 391671</phone>
      <phone_ext>7210</phone_ext>
      <email>peter.vorwerk@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim gGmbH, Kinderklinik, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Dürken</last_name>
      <phone>+49 621383</phone>
      <phone_ext>2244</phone_ext>
      <email>matthias.duerken@kikli.ma.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Dürken, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Erdlenbruch</last_name>
      <phone>+49 571</phone>
      <phone_ext>8010</phone_ext>
      <email>bernhard.erdlenbruch@klinikum-minden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städt. Krankenhaus München GmbH, Krankenhaus München-Schwabingen, Kinderklinik d. TU</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Wawer</last_name>
      <phone>+49 893068</phone>
      <phone_ext>2261</phone_ext>
      <email>angela.wawer@lrz.tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik, Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Rössig</last_name>
      <phone>+49 251834</phone>
      <phone_ext>5644</phone_ext>
      <email>rossig@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cnopf'sche Kinderklinik, Onkologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Scheurlen</last_name>
      <phone>+49 91133</phone>
      <phone_ext>40323</phone_ext>
      <email>wolfram.scheurlen@diakonieneudettelsau.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH, Zentrum für Kinder- u. Jugendmedizin, (Elisabeth Kinderkrankenhaus)</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Müller</last_name>
      <phone>+49 441403</phone>
      <phone_ext>2013</phone_ext>
      <email>mueller.hermann@klinikum-oldenburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selim Corbacioglu, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl-Friedrich Classen</last_name>
      <phone>+49 381494</phone>
      <phone_ext>7000</phone_ext>
      <email>carl-friedrich.classen@med.uni-rostock.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios-Klinik, Sankt Augustin GmbH</name>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Reinhard</last_name>
      <phone>+49 224124</phone>
      <phone_ext>9304</phone_ext>
      <email>h.reinhard@asklepios.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken Schwerin, Klinik f. Kinder-u. Jugendmedizin</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Güttel</last_name>
      <phone>+49 385520</phone>
      <phone_ext>2710</phone_ext>
      <email>christian.guettel@helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Olga-Hospital, Kinderklinik, Pädiatrisches Zentrum, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bielack</last_name>
      <phone>+49 711992</phone>
      <phone_ext>2461</phone_ext>
      <email>st.bielack@olgahospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Trier, Mutterhaus der Borromaeerinnen, Pädiatrische Abteilung</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Weis</last_name>
      <phone>+49 651947</phone>
      <phone_ext>2654</phone_ext>
      <email>weis@mutterhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Ebinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus M. Debatin, MD</last_name>
      <phone>49-731-5000</phone>
      <email>klaus-michael.debatin@medizin.uni-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stadtkrankenhaus, Kinderklinik</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Mukodzi</last_name>
      <phone>+49 5361</phone>
      <phone_ext>8000</phone_ext>
      <email>sally.mukidzi@klinikum-wolfsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. G. Schlegel, MD</last_name>
      <phone>49-931-2012-7856</phone>
      <email>schlegel@mail.uni-wuerzburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Kapelushnik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nira Arad-Cohen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gal Goldstein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children Medical Center of Israel</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gil Gilad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center Tel-Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bella Bielorai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana children hospital</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronit Elhasid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedali riuniti</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Pierani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOUC Policlinico Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Santoro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Provenzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Pession</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fulvio Porta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Maria Mura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero universitaria</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Lo Nigro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Consarino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.O. Annunziata - A. O. Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Sperlì</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tommaso Casini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Micalizzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Cellini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica pediatrica Fondazione MBBM</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Biondi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Rossi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AORN Santobono Pausilipon</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosanna Parasole</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Caterina Putti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civico ARNAS Civico e Di Cristina</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ottavio Ziino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero-universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelica Barone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Zecca</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria della misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Caniglia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Onofrillo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela De Marco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grande ospedale metropolitano B-M-M</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Ronco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale infermi</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Pericoli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Ruggiero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I Università Sapienza di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Foà</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Casa sollievo della sofferenza&quot;</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saverio Ladogana</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della salute e della scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Kiren</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Cesaro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika pediatrickej hematológie a onkológie SZU a DFNsP</name>
      <address>
        <city>Banská Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Bubanská</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comenius University Children's Hospital</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Kolenova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Detská fakultná nemocnica Košice</name>
      <address>
        <city>Košice</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natália Galóová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Scheinemann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital beider Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas von der Weid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bellinzona</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierluigi Brazzola</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Rössler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HUG Hôpitaux Universitaires de Gèneve</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Baleydier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Ceppi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital-Kinderspital Luzern</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freimut Schilling</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ostschweizer Kinderspital</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Greiner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Niggli</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Martin Schrappe</investigator_full_name>
    <investigator_title>Professor MD, FRCP (Glasg), Chair of Pediatrics I</investigator_title>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Childhood</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Blinatumomab</keyword>
  <keyword>Proteasome Inhibitor</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Blinatumomab</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

